This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Flamel Technologies SA Q2 2010 Earnings Call Transcript

Flamel Technologies SA, (FLML)

2Q 2010 Earnings Call

July 29, 2010 08:30 am ET


Stephen Willard

Sian Crouzet


Matt Kaplan – Ladenburg

Peter Butler – Glen Hill Investments

Edward Nash – Roth Capital Partners

David Moskowitz – Madison Williams



Please stand by, good morning ladies and gentlemen and welcome to the Flamel Technologies Second Quarter Earnings Conference Call. Please note that this call is being recorded.

Flamel Technologies requests that all investors review the forward looking statement language which is set out at the conclusion of yesterday’s press release.

All statements made on this call are subject to a variety of future events and risk factors including those set forth in Flamel’s filings with the SEC particularly on form 20-F, which are all publically available. Please review them as they are directly ethical to every element of this call.

I’d now like to turn the call over to Mr. Stephen Willard, please go ahead sir.

Stephen Willard

Thank you very much Rochelle and good morning ladies and gentlemen. Since our last quarterly call in May we have made important progress as highlighted in the press release detailing our second quarter results we are pleased with the progress that we have made recently particularly in the work we are undertaking with Merck Serono and Pfizer as well as a number of our other partners.

Excluding currency impacts we increased cash reserves during the second quarter. We maintain our cash reserves in Euros so as to match our expenditures.

Operationally we are pleased to announce the addition of three new programs as detailed in yesterday’s press release. Two of these programs are with a single partner for the development of controlled release formulations for cardiovascular drugs using our Micropump platforms.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FLML $11.46 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs